In this context, we previously demonstrated that miR-211 plays a role in Bcl-2-induced melanoma promoting functions2, miR-579-3p controls melanoma progression and resistance to target therapy3, and miR-25 is involved in the regulation of PTEN expression by MEK inhibition4. The gene discussed is BCL2; the disease is melanoma.